Immuneering (IMRX) Total Liabilities (2020 - 2026)

Immuneering's Total Liabilities history runs 7 years deep, the most recent figure standing at $8.3 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 6.19% year-over-year to $8.3 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 6.19% decrease from a year earlier, with the FY2025 full-year figure at $13.5 million, up 19.18% from the prior year.
• Total Liabilities eased to $8.3 million in Q1 2026 per IMRX's latest filing, from $13.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $13.5 million in Q4 2025 and bottomed at $8.3 million in Q1 2026.
• The 5-year median for Total Liabilities is $10.8 million (2024), against an average of $10.6 million.
• Across the five-year window, Total Liabilities jumped 105.23% in 2022 and dropped 16.4% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $12.5 million in 2022, then decreased by 4.06% to $12.0 million in 2023, then decreased by 5.66% to $11.3 million in 2024, then increased by 19.18% to $13.5 million in 2025, then sank by 38.59% to $8.3 million in 2026.
• Per Business Quant, the three latest IMRX Total Liabilities figures stand at $8.3 million (Q1 2026), $13.5 million (Q4 2025), and $13.1 million (Q3 2025).